Kriya Therapeutics to Advance Gene Therapies with $100 Million Financing

Published on: 

Kriya Therapeutics completes $100 Million Series B financing to advance its platform for designing, developing, and manufacturing gene therapies.

Kriya Therapeutics announced in a July 14, 2021 press release the closing of a $100 million Series B financing to support the design, development, and manufacturing of gene therapies.

According to the press release, the financing proceeds will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline, and advance its current programs in metabolic disease, ophthalmology, and oncology.

“With the support of our new and existing investors, we believe that Kriya is well positioned to deliver transformative improvements in cost, scale, and efficiency that will help the gene therapy field achieve its full potential across a range of therapeutic areas,” said Shankar Ramaswamy, co-founder and CEO of Kriya Therapeutics, in a press release.


The financing was led by Patient Square Capital, with participation from Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures, and other new investors. All existing institutional investors also participated.

Source: Kriya Therapeutics